The 2023 FIGO staging system designated stage I-II low-grade endometrioid endometrial carcinoma with p53-abn as stage IICmp53abn [10], and, as a result, p53 IHC screening is likely to be beneficial in all patients with early-stage disease. The gene discussed is TP53; the disease is endometrial endometrioid carcinoma.